Livionex, Inc., which is based in Los Gatos, Calif., released the results of a double blind clinical trial study on reduction of plaque, gingivitis, and gum bleeding. The study was conducted at the Beckman Laser Institute of UC Irvine and compared Livionex Dental Gel to Colgate Total, the leading ADA and FDA approved anti-plaque, anti-gingivitis toothpaste.
Livionex said the results revealed 260% reduction in plaque index, 229% reduction in gingivitis index, and a 232% reduction in gum bleeding index when compared to Colgate Total. The results were published in the journal “Lasers in Surgery and Medicine.”
The Livionex formulation uses activated Edathamil to break up the bond between the plaque biofilm and teeth.
Amit Goswamy, the CEO of Livionex, commented, “We are very pleased with the results of the UC Irvine study and the interest it is generating across the industry. It validates our 10 years of R&D. The Livionex team is excited that the dental gel will pave the way to combat America’s silent epidemic of gingivitis and periodontitis.”
Dr. Peter Jacobson, a dental pharmacologist said, “Any product that can improve the effectiveness of tooth brushing at a level demonstrated by Livionex is not only a breakthrough, but can be categorized as a disruptive innovation with major public health implications. It redefines what toothpaste and oral hygiene are all about.”
Livionex Inc. was founded in 2009. Its technology is the result of over 10 years of extensive research by key members of the Livionex team in close collaboration with scientists at research institutions such as the University of Texas and the University of California. Livionex is a recipient of research grants from the US National Institutes of Health (NIH) and the US Department of Defense (DOD).
In addition to Livionex Dental Gel, the company is leveraging its technology platform to develop products targeting large unmet medical needs in oral care, ophthalmology, and dermatology.
The dental gel is currently available on-line at www.livionexdental.com.
